Add on studies
- Hepatic VLDL-TG production test in the same animals (hepatic lipogenesis index)
- Fecal analysis to estimate the effect of your compound on lipid excretion in the same animals
- Glucose tolerance testing in the same animals.
First in vivo proof of concept of the impact of your compound designed to treat type 2 diabetes on cardiovascular complications due to dyslipidemia or hypercholesterolemia, in terms of whole-body lipid homeostasis.
This experiment investigates how triglycerides/cholesterol intestinal absorption is improved with your compound after lipid intake.
This experiment investigates how triglycerides/cholesterol intestinal absorption is improved with your compound after lipid intake.
Key benefits
- Large-scale screening with an in vivo technique on triglycerides/cholesterol absorption
- In vivo insights into your compound's efficacy in inhibiting intestinal lipid absorption
- Sensitivity to detect a statistically significant impact of your compound on postprandial blood lipid regulation
Species
- Rat
- Mouse
